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General Considerations  
 
 
(A) General Analytical Information. 
  Nuclear Magnetic Resonance spectra were recorded on a Bruker Avance 400 MHz and 600 MHz 
instruments at ambient temperature. All 1H NMR spectra were measured in part per million (ppm) relative 
to the signal of tetramethylsilane (TMS) added into the deuterated chloroform (CDCl3, 0.00 ppm), the 
signal of residual dichloromethane in deuterated dichloromethane (CD2Cl2, 5.32 ppm), or the signal of 
residual dimethyl sufloxide in dimethyl-d6 sufloxide (DMSO-d6, 2.50 ppm).
1 Data for 1H NMR were 
reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quint = 
quintet, sex = sextet, m = multiplet, br = broad), coupling constants, and integration. All 13C NMR spectra 
were reported in ppm relative to CDCl3 (77.16 ppm), CD2Cl2 (53.84 ppm), or DMSO-d6 (39.52 ppm)
1 and 
were obtained with complete 1H decoupling. All 19F NMR spectra were reported in ppm relative to 
hexafluorobenzene as an internal standard (-164.9 ppm, with reference to CFCl3 at 0 ppm) or relative to 
CFCl3 (0 ppm) as an external standard, and were obtained with complete 
1H decoupling. All gas 
chromatography (GC) analyses were performed on a Perkin-Elmer Clarus 400 GC system with a FID 
detector. All gas chromatography-mass spectrometry (GC-MS) analyses were performed on an Agilent 
Technologies 7890A GC system equipped with a 5975C MS detector. High-resolution mass spectra 
(HRMS) by electrospray ionization (ESI) method were performed at the EPFL ISIC Mass Spectroscopy 
Service with a Micro Mass QTOF Ultima spectrometer. Melting points (Mp) of solid compounds were  
performed using SGW X-4 micro-melting point apparatus. Infra-red (IR) spectroscopies were performed 
using Bruker Vertex 70 spectrometer.  
 
 
(B) General Reagent Information. 
  Unless otherwise noted, all chemicals were used as received without further purifications. N-
Methylpyrrolidone (NMP) was dried using 3Å molecular sieve beads. Manganese powder was in 99.9% 
purities. Iodotrimethylsilane was stabilized using copper strips and was kept at refrigerator prior to use. 
The following known starting materials (tertiary amides and nitroarenes) were prepared according to the 
literature procedures:2-29 
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(C) General Manipulation Considerations.    
   
  All manipulations for the Mn-mediated reductive transamidation of tertiary amides with nitroarenes were 
set up in either two ways (1) in a 25 mL Schlenk tube under an inert argon (Ar) atmosphere; (2) in a 30 mL 
Teflon-screw capped test tubes under an inert nitrogen (N2) atmosphere using glove-box techniques. Flash 
column chromatography was performed using 200-300 mesh silica gel. Preparative thin-layer 
chromatography (preparative TLC) was performed using preparative TLC plate (Merck Millipore, TLC 
Silica gel 60 F254, 20 x 20 cm, catalogue number: 1.05715.0001) in a developing tank. Notably, the TLC 
plates used for the purification of amide products were washed with hexanes/triethylamine solution 
(volume ratio ~20:1) prior to use in order to minimize the product loss. The eluents for column 
chromatography and preparative TLC were presented as ratios of solvent volumes. Yields reported in the 
publication are of isolated materials unless otherwise noted. All new starting materials and amide products 
were characterized by 1H and 13C NMR spectroscopies, high-resolution mass spectrometry (HRMS), thin-
layer chromatography (TLC, Rf value), and melting point analysis (Mp, for solid compounds), and most of 
them were further characterized by infra-red spectrosmetry (IR). All known starting materials and amide 
products were characterized by 1H and 13C NMR spectroscopies and the spectra were compared with the 
reported data when provided.  
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Figure S1. Study of possibility of transamidation of tertiary amides with anilines.  
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Experimental Section  
 
 
Synthesis of Starting Materials:  
 
 
General Procedures for the Synthesis of Tertiary Amides (General Procedures A). 
 
  An oven-dried 500 mL round-bottom flask equipped with a Teflon-coated magnetic stir bar was 
sequentially charged with dichloromethane solvent (CH2Cl2), amide, and base (triethylamine (Et3N) or 
pyridine). The reaction mixture was stirred at room temperature, and acyl chloride was slowly added for 
~1 minute into the reaction mixture. The resulting mixture was stirred at room temperature overnight. 
After the reaction, the organic fraction was washed with HCl solution (~1 M (aq), ~100 mL), followed 
by NaOH solution (~1 M (aq), ~100 mL) and finally saturated NaCl solution (~50 mL). The organic 
fraction was dried with anhydrous MgSO4 and then concentrated in vacuo with the aid of a rotary 
evaporator. The residue was purified by flash column chromatography using a mixture of 
hexanes/EtOAc as an eluent to afford the tertiary amide.  
 
 
 
N,N-Diphenylcyclobutanecarboxamide (S1). Following the general procedure A, the title compound 
was prepared using cyclobutanecarbonyl chloride (2 equiv, 10 mmol, 1.14 mL), diphenylamine (1 equiv, 
5 mmol, 845 mg), pyridine (4 equiv, 3.9 mmol, 1.6 mL), and CH2Cl2 (100 mL) using hexanes/EtOAc 
(10:1) as an eluent to afford the title compound as a white amorphous solid (917 mg, 73%). 1H NMR 
(400 MHz, CDCl3): δ 7.34 (br s, 4 H), 7.27-7.10 (m, 6 H), 3.17 (quint, J = 8.1 Hz, 1 H), 2.46-2.34 (m, 
2 H), 1.89-1.75 (m, 4 H). 13C NMR (100 MHz, CDCl3): δ 174.9, 142.9, 129.2 (br), 126.4 (br), 39.1, 
26.0, 17.9 (7 carbon signals were observed out of expected 8 carbon signals). HRMS (ESI): Calcd for 
C17H18NO [M+H]: 252.1388; Found: 252.1418. Mp: 76-78 
oC. Rf  = 0.72 (EtOAc : petroleum ether = 
1:2). IR (neat, cm-1): 2987, 2359, 1489, 1260, 1066.  
 
 
 
N,N-Diphenylcyclopentanecarboxamide (S2). Following the general procedure A, the title compound 
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was prepared using cyclopentanecarbonyl chloride (2 equiv, 10 mmol, 1.22 mL), diphenylamine (1 
equiv, 5 mmol, 845 mg), pyridine (4 equiv, 3.9 mmol, 1.6 mL), and CH2Cl2 (100 mL) using 
hexanes/EtOAc (10:1) as an eluent to afford the title compound as a white amorphous solid (863 mg, 
65%). 1H NMR (400 MHz, CDCl3): δ 7.34 (br s, 4 H), 7.29-7.14 (m, 6 H), 2.76 (quint, J = 7.8 Hz, 1 H), 
1.96-1.86 (m, 2 H), 1.80-1.66 (m, 4 H), 1.49-1.39 (m, 2 H). 13C NMR (100 MHz, CDCl3): δ 177.2, 
143.3, 129.3 (br), 126.9 (br), 43.0, 31.4, 26.5 (7 carbon signals were observed out of expected 8 carbon 
signals). HRMS (ESI): Calcd for C18H20NO [M+H]: 266.1545; Found: 266.1554. Mp: 78-80 
oC. Rf  = 
0.75 (EtOAc : petroleum ether = 1:2). IR (neat, cm-1): 2955, 2362, 1672, 1488, 1364, 1248. 1069. 
 
 
 
N-Butyl-N-phenyl-4-(trifluoromethoxy)benzamide (S3). Following the general procedure A, the title 
compound was prepared using 4-(trifluoromethoxy)benzoyl chloride (1 equiv, 5.0 mmol, 0.79 mL), N-
n-butylaniline (1.05 equiv, 5.25 mmol, 783 mg), Et3N (1.5 equiv, 7.5 mmol, 1.0 mL), and CH2Cl2 (100 
mL) using hexanes/EtOAc (5:1) as an eluent to afford the title compound as a brown oil (1.12 g, 72%). 
1H NMR (400 MHz, CD2Cl2): δ 7.39 (d, J = 8.0 Hz, 2 H), 7.25 (t, J = 7.2 Hz, 2 H), 7.16 (t, J = 7.1 Hz, 
1 H), 7.08 (d, J = 7.4 Hz, 2 H), 7.03 (d, J = 7.9 Hz, 2 H), 3.95 (t, J = 7.1 Hz, 2 H), 1.64 (quint, J = 7.1 
Hz, 2 H), 1.39 (hex, J = 7.3 Hz, 2 H), 0.93 (t, J = 7.1 Hz, 3 H). 13C NMR (100 MHz, CD2Cl2): δ 169.0, 
150.0, 143.8, 136.0, 130.9, 129.6, 128.4, 127.2, 120.9 (q, 1JCF = 255.8 Hz), 120.3, 50.7, 30.3, 20.7, 14.1. 
HRMS (ESI): Calcd for C18H19F3NO2 [M+H]: 338.1368; Found: 338.1374. 19F NMR (376 MHz, 
CDCl3, C6F6 as internal standard): δ -61.0. Rf  = 0.61 (EtOAc : petroleum ether = 1:2). IR (neat, cm-1): 
1643, 1586, 1494, 1390, 1254, 1210, 1180, 857.  
 
 
 
(4-(Dimethylamino)phenyl)(indolin-1-yl)methanone (S4). Following the general procedure A, the 
title compound was prepared using 4-(N,N-dimethylamino)benzoyl chloride (1 equiv, 2.6 mmol, 477 
mg), indoline (1.2 equiv, 3.12 mmol, 0.35 mL), Et3N (1.5 equiv, 3.9 mmol, 0.53 mL), and CH2Cl2 (60 
mL) using hexanes/EtOAc (3:1) as an eluent to afford the title compound as a pale-brown amorphous 
solid (623 mg, 90%). 1H NMR (400 MHz, CDCl3): δ 7.57-7.36 (m, 3 H), 7.19 (d, J = 6.9 Hz, 1 H), 7.10 
(t, J = 6.8 Hz, 1 H), 6.97 (t, J = 7.0 Hz, 1 H), 6.68 (d, J = 8.3 Hz, 2 H), 4.15 (t, J = 8.0 Hz, 2 H), 3.09 (t, 
J = 8.0 Hz, 2 H), 3.03 (s, 6 H). 13C NMR (100 MHz, CDCl3): δ 169.6, 152.1, 143.6, 132.5, 129.7, 127.2, 
124.9, 123.6, 123.3, 117.0, 111.2, 51.0, 40.3, 28.4. HRMS (ESI): Calcd for C17H19N2O [M+H]: 
267.1497; Found: 267.1498. Mp: 144-146 oC. Rf  = 0.44 (EtOAc : petroleum ether = 1:2). IR (neat, cm-
1): 2362, 1629, 1608, 1478, 1392, 1367, 1343, 1192, 1157, 817.   
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(4-Fluorophenyl)(indolin-1-yl)methanone (S5).30 Following the general procedure A, the title 
compound was prepared using 4-fluorobenzoyl chloride (1 equiv, 3 mmol, 0.36 mL), indoline (1.3 equiv, 
3.9 mmol, 0.44 mg), Et3N (1.5 equiv, 4.5 mmol, 0.6 mL), and CH2Cl2 (60 mL) using hexanes/EtOAc 
(5:1) as an eluent to afford the title compound as a white amorphous solid (510 mg, 71%). 1H NMR 
(400 MHz, CDCl3): δ 8.13 (br s, 1 H), 7.57 (dd, 3JHH = 8.6 Hz, 4JHF = 5.4 Hz, 2 H), 7.21 (d, J = 7.1 Hz, 
1 H), 7.20-7.06 (m, 3 H), 7.02 (t, J = 7.5 Hz, 1 H), 4.07 (t, J = 8.0 Hz, 2 H), 3.12 (t, J = 8.3 Hz, 2 H). 
13C NMR (100 MHz, CDCl3): δ 168.0, 163.9 (1JCF = 249.2 Hz), 142.6, 133.1, 132.5, 129.7 (3JCF = 8.1 
Hz), 127.3, 125.1, 124.1, 117.0, 115.8 (2JCF = 21.7 Hz), 50.8, 28.2. HRMS (ESI): Calcd for C15H13FNO 
[M+H]: 242.0981; Found: 242.0981. 
 
 
  
(4-Chlorophenyl)(indolin-1-yl)methanone (S6).30 Following the general procedure A, the title 
compound was prepared using 4-chlorobenzoyl chloride (1 equiv, 3 mmol, 0.38 mL), indoline (1.3 equiv, 
3.9 mmol, 0.44 mL), Et3N (1.5 equiv, 4.5 mmol, 0.6 mL), and CH2Cl2 (60 mL) using hexanes/EtOAc 
(5:1) as an eluent to afford the title compound as a white amorphous solid (550 mg, 71%). 1H NMR 
(400 MHz, CDCl3): δ 8.14 (br s, 1 H), 7.50 (d, J = 8.4 Hz, 2 H), 7.42 (d, J = 8.5 Hz, 2 H), 7.26-7.13 (m, 
2 H), 7.03 (t, J = 7.4 Hz, 1 H), 4.06 (br s, 2 H), 3.12 (t, J = 8.2 Hz, 2 H). 13C NMR (100 MHz, CDCl3): 
δ 167.9, 142.5, 136.5, 135.3, 132.4, 129.0, 128.9, 127.4, 125.1, 124.3, 117.2, 50.8, 28.2. HRMS (ESI): 
Calcd for C15H13ClNO [M+H]: 258.0686; Found: 258.0685. 
 
 
 
Indolin-1-yl(thiophen-2-yl)methanone (S7).31 Following the general procedure A, the title compound 
was prepared using thiophene-2-carbonyl chloride (1 equiv, 10 mmol, 1.1 mL), indoline (1.3 equiv, 13 
mmol, 1.5 mL), Et3N (1.5 equiv, 15 mmol, 2.1 mL), and CH2Cl2 (150 mL) using hexanes/EtOAc (3:1) 
as an eluent to afford the title compound as an off-white amorphous solid (2.09 g, 91%). 1H NMR (400 
MHz, CDCl3): δ 8.08 (br s, 1 H), 7.53 (dd, J = 3.8 Hz, J = 1.0 Hz, 1 H), 7.49 (dd, J = 5.0 Hz, J = 1.1 
Hz, 1 H), 7.20-7.17 (m, 2 H), 7.07 (dd, J = 5.0 Hz, J = 3.8 Hz, 1 H), 7.02 (td, J = 7.5 Hz, J = 0.9 Hz, 1 
H), 4.30 (t, J = 8.3 Hz, 2 H), 3.15 (t, J = 8.1 Hz, 2 H). 13C NMR (100 MHz, CDCl3): δ 161.4, 143.0, 
139.5, 131.9, 130.2, 129.7, 127.4, 127.2, 124.7, 124.2, 117.7, 50.6, 28.6.  
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1-(Indolin-1-yl)-3-phenylpropan-1-one (S8).32 Following the general procedure A, the title compound 
was prepared using 3-phenylpropanoyl chloride (1 equiv, 3 mmol, 5.1 mL), indoline (1.1 equiv, 3.3 
mmol, 0.37 mL), Et3N (1.5 equiv, 4.5 mmol, 0.6 mL), and CH2Cl2 (60 mL) using hexanes/EtOAc (3:1) 
as an eluent to afford the title compound as a white amorphous solid (511 mg, 2.03 mmol, 62%). 1H 
NMR (400 MHz, CDCl3): δ 8.26 (d, J = 8.0 Hz, 1 H), 7.31-7.23 (m, 4 H), 7.3-7.13 (m, 3 H), 6.99 (t, J 
= 7.4 Hz, 1 H), 3.92 (t, J = 8.4 Hz, 2 H), 3.11 (t, J = 8.4 Hz, 2 H), 3.06 (t, J = 8.0 Hz, 2 H), 2.70 (t, J = 
Hz, 2 H). 13C NMR (100 MHz, CDCl3): δ 170.4, 143.1, 141.3, 131.1, 128.6, 128.5, 127.6, 126.3, 124.6, 
123.6, 117.1, 48.0, 38.0, 30.8, 28.1. HRMS (ESI): Calcd for C17H18NO [M+H]: 252.1388; Found: 
252.1386. 
 
 
 
1-(Indolin-1-yl)decan-1-one (S9). Following the general procedure A, the title compound was prepared 
using decanoyl chloride (1 equiv, 10 mmol, 1.91 g), indoline (1.3 equiv, 13 mmol, 1.46 mL), Et3N (1.5 
equiv, 15 mmol, 2.1 mL), and CH2Cl2 (150 mL) using hexanes/EtOAc (5:1) as an eluent to afford the 
title compound as a white amorphous solid (2.27 g, 83%). 1H NMR (400 MHz, CDCl3): δ 8.24 (d, J = 
8.0 Hz, 1 H), 7.19-7.14 (m, 2 H), 6.99 (d, J = 7.4 Hz, 1 H), 4.02 (d, J = 8.5 Hz, 2 H), 3.17 (d, J = 8.4 
Hz, 2 H), 2.39 (d, J = 7.5 Hz, 2 H), 1.72 (quint, J = 7.3 Hz, 2 H), 1.40-1.24 (m, 12 H), 0.88 (t, J = 6.7 
Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 171.6, 143.2, 131.1, 127.6, 124.5, 123.5, 117.1, 48.0, 36.1, 
32.0, 29.61, 29.59, 29.52, 29.4, 28.1, 24.7, 22.8, 14.2. GCMS: [M]+ = 273 was detected, which 
corresponds to C18H27NO ([M]
+ could not be detected by HRMS). Mp: 45-47 oC. Rf  = 0.70 (EtOAc : 
petroleum ether = 1:2).IR (neat, cm-1): 2922, 1655, 1482, 1461, 1409, 1261.  
 
 
 
1-(1H-Pyrazol-1-yl)decan-1-one (S10). Following the general procedure A, the title compound was 
prepared using decanoyl chloride (1 equiv, 10 mmol, 1.91 g), pyrazole (1.5 equiv, 15 mmol, 1.02 g), 
Et3N (1.5 equiv, 15 mmol, 2.1 mL), and CH2Cl2 (150 mL) using hexanes/EtOAc (5:1) as an eluent to 
afford the title compound as a colorless oil (1.73 g, 78%). 1H NMR (400 MHz, CDCl3): δ 8.26 (d, J = 
2.8 Hz, 1 H), 7.69 (s, 1 H), 6.42 (dd, J = 2.0 Hz, J = 1.3 Hz, 1 H), 3.13 (t, J = 7.5 Hz, 2 H), 1.78 (quint, 
J = 7.5 Hz, 2 H), 1.43-1.27 (ovlp, 12 H), 0.88 (t, J = 6.2 Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 
172.3, 143.8, 128.2, 109.4, 34.0, 31.9, 29.5, 29.4, 29.3, 29.2, 24.4, 22.7, 14.1. HRMS (ESI): Calcd for 
C13H22N2ONa [M+Na]: 245.1630; Found: 245.1630. Rf  = 0.76 (EtOAc : petroleum ether = 1:2).IR 
(neat, cm-1): 2923, 2854, 1736, 1413, 1382, 1343, 1247, 1199, 1088, 1037, 915.  
 
 
 
(Adamantan-1-yl)(1H-pyrazol-1-yl)methanone (S11). Following the general procedure A, the title 
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compound was prepared using 1-adamantanecarbonyl chloride (1 equiv, 6 mmol, 1.19 mL), pyrazole (2 
equiv, 12 mmol, 817 mg), Et3N (1.5 equiv, 9.0 mmol, 1.25 mL), and CH2Cl2 (100 mL) using 
hexanes/EtOAc (5:1) as an eluent to afford the title compound as a white amorphous solid (1.11 g, 80%). 
1H NMR (400 MHz, CD2Cl2): δ 8.23 (d, J = 2.6 Hz, 1 H), 7.68 (s, 1 H), 6.35 (dd, J = 2.4 Hz, J = 1.4 
Hz, 1 H), 2.33-2.28 (m 6 H), 2.09-2.05 (m, 3 H), 1.94-1.75 (m, 6 H). 13C NMR (100 MHz, CD2Cl2): δ 
175.9, 143.2, 130.3, 108.1, 44.2, 38.9, 37.0, 28.8. HRMS (ESI): Calcd for C14H18N2ONa [M+Na]: 
253.1317; Found: 253.1321. Mp: 98-100 oC. Rf  = 0.94 (EtOAc : petroleum ether = 1:2). IR (neat, cm-
1): 2908, 1745, 1541, 1374, 1333, 1311, 1205, 911.  
  
 
 
Indolin-1-yl(3,4,5-trimethoxyphenyl)methanone (S12).33 Following the general procedure A, the title 
compound was prepared using 3,4,5-trimethoxybenzoyl chloride (1 equiv, 10 mmol, 2.31 g), indoline 
(1.2 equiv, 12 mmol, 1.4 mL), Et3N (1.5 equiv, 15 mmol, 2.1 mL), and CH2Cl2 (150 mL) using 
hexanes/EtOAc (1:3) as an eluent to afford the title compound as an off-white amorphous solid (2.66 g, 
85%). 1H NMR (400 MHz, CDCl3): δ 7.75 (br s, 1 H), 7.07 (d, J = 7.0 Hz, 1 H), 6.99 (br s, 1 H), 6.88 
(t, J = 7.1 Hz, 1 H), 6.68 (s, 2 H), 3.97 (t, J = 8.2 Hz, 2 H), 3.77 (s, 3 H), 3.73 (s, 6 H), 2.97 (d, J = 7.9 
Hz, 2 H). 13C NMR (100 MHz, CDCl3): δ 168.2, 153.1, 142.3, 139.5, 132.2, 132.0, 126.9, 124.7, 123.7, 
116.5, 104.3, 60.6, 56.0, 50.3, 27.8. HRMS (ESI): Calcd for C18H20NO4 [M+H]: 314.1392; Found: 
314.1397.  
 
 
 
 
General Procedures for the Synthesis of Tertiary Amides (General Procedures B).  
 
An oven-dried 500 mL round-bottom flask equipped with a Teflon-coated magnetic stir bar was 
sequentially charged with dichloromethane solvent (CH2Cl2), NH-free tertiary amide, and triethylamine 
(Et3N). The reaction mixture was stirred at room temperature, and acyl chloride (or triflic anhydride) 
was slowly added for ~1 minute into the reaction mixture. The resulting mixture was stirred at room 
temperature overnight. After the reaction, the organic fraction was washed with dilute HCl solution (~1 
M (aq), ~100 mL), followed by dilute NaOH solution (~1 M (aq), ~50 mL), and finally saturated NaCl 
solution (~50 mL). The organic fraction was dried with anhydrous MgSO4 powder and then concentrated 
in vacuo with the aid of a rotary evaporator. The residue was purified by flash chromatography using a 
mixture of hexanes/EtOAc as an eluent to afford the N-protected tertiary amide.  
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1-(4-Benzoylpiperazin-1-yl)-2,2-dimethylpropan-1-one (S13). Following the general procedure B, 
the title compound was prepared using phenyl(piperazin-1-yl)methanone (1 equiv, 5.5 mmol, 1.05 g), 
pivaloyl chloride (2 equiv, 11 mmol, 1.36 mL), Et3N (1.5 equiv, 8.25 mmol, 1.14 mL), and CH2Cl2 (100 
mL) using hexanes/EtOAc (1:10) as an eluent to afford the title compound as a white amorphous solid 
(1.43 g, 95%). 1H NMR (400 MHz, CD2Cl2): δ 7.46-7.38 (m, 5 H), 4.21-3.10 (br m, 8 H), 1.26 (s, 9 H). 
13C NMR (100 MHz, CD2Cl2): δ 176.6, 170.5, 136.1, 130.1, 128.8, 127.4, 47.9 (br), 45.4, 42.5 (br), 
38.9, 28.5 (11 carbon signals were observed out of expected 12 carbon signals). HRMS (ESI): Calcd 
for C16H23N2O2 [M+H]: 275.1760; Found: 275.1658. Mp: 125-127 
oC. Rf  = 0.16 (EtOAc : petroleum 
ether = 1:2). IR (neat, cm-1): 1612, 1427, 1281, 1253, 1185, 1006.  
 
 
 
Phenyl(4-((trifluoromethyl)sulfonyl)piperazin-1-yl)methanone (S14). Following the general 
procedure B, the title compound was prepared using phenyl(piperazin-1-yl)methanone (1 equiv, 4.0 
mmol, 761 mg), triflic anhydride (2 equiv, 8.0 mmol, 1.35 mL), Et3N (1.5 equiv, 6.0 mmol, 0.83 mL), 
and CH2Cl2 (100 mL) using hexanes/EtOAc (1:8) as an eluent to afford the title compound as a an off-
white amorphous solid (1.04 g, 81%). 1H NMR (400 MHz, CDCl3): δ 7.46-7.35 (m, 5 H), 4.55-3.17 (br 
m, 8 H). 13C NMR (100 MHz, CDCl3): δ 170.3, 134.4, 130.1, 128.5, 126.9, 118.3 (q, 1JCF = 321.3 Hz), 
46.8 (br), 46.3, 42.0 (br) (9 carbon signals were observed out of expected 10 carbon signals). HRMS 
(ESI): Calcd for C12H14F3N2O3S [M+H]: 323.0677; Found: 323.0681. 19F NMR (376 MHz, CDCl3, 
C6F6 as internal standard): δ -75.3. Mp: 74-76 oC. Rf  = 0.41 (EtOAc : petroleum ether = 1:2). IR (neat, 
cm-1): 1790, 1635, 1432, 1384, 1227, 1188, 1153, 1104, 954.   
 
 
 
 
Synthesis of (9H-Carbazol-9-yl)(cyclopropyl)methanone (S15).  
 
An oven-dried 500 mL round-bottom flask equipped with a Teflon-coated magnetic stir bar was 
sequentially charged with anhydrous dimethylformamide solvent (DMF, 100 mL) and carbazole (1 
equiv, 10 mmol, 1.67 g). The reaction mixture was stirred at room temperature, and NaH (~60% in 
mineral oil, 2 equiv, 20 mmol, ~780 mg) in a few portions was slowly added for ~1 minute 
. The reaction mixture was stirred at room temperature for 1 h, after which time cyclopropanecarbonyl 
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chloride (1.5 equiv, 15 mmol, 1.36 mL) was slowly added for ~1 minute and the resulting mixture was 
stirred at room temperature for 2 h. After that, another portion of cyclopropanecarbonyl chloride (1.5 
equiv, 15 mmol, 1.36 mL) was added and the resulting mixture was stirred at room temperature 
overnight. After the reaction, the reaction was quenched with water (~20 mL), and the reaction mixture 
was washed with water (~500 mL) and ethyl acetate (EtOAc, ~100 mL). The organic fraction was further 
washed with dilute NaOH solution (~1 M (aq), ~50 mL) followed by saturated NaCl solution (~50 mL). 
The organic fraction was dried with anhydrous MgSO4 and then concentrated in vacuo with the aid of a 
rotary evaporator. The residue was recrystallized using CH2Cl2 and hexanes as solvent to afford the title 
compound as a white amorphous solid (1.53 g, 65%). 1H NMR (400 MHz, CDCl3): δ 8.22 (d, J = 8.3 
Hz, 2 H), 7.97 (dd, J = 7.6 Hz, J = 0.6 Hz, 2 H), 7.44 (td, J = 7.4 Hz, J = 1.3 Hz, 2 H), 7.35 (td, J = 7.6 
Hz, J = 0.8 Hz, 2 H), 2.55-2.49 (m, 1 H), 1.49-1.45 (m, 2 H), 1.21-1.16 (m, 2 H). 13C NMR (100 MHz, 
CDCl3): δ 173.9, 138.8, 127.1, 126.1, 123.3, 120.0, 115.6, 17.7, 10.3. HRMS (ESI): Calcd for C16H14NO 
[M+H]: 236.1075; Found: 236.1079. Mp: 72-74 oC. Rf  = 0.88 (EtOAc : petroleum ether = 1:2). IR 
(neat, cm-1): 2974, 1670, 1442, 1396, 1286, 1160, 1067, 914.  
  
 
 
 
Synthesis of (4-(4-Nitrophenoxy)phenyl)(phenyl)methanone (S16).  
 
An oven-dried 500 mL round-bottom flask equipped with a Teflon-coated magnetic stir bar was charged 
with 1-fluoro-4-nitrobenzene (1 equiv, 8 mmol, 1.13 g), 4-hydroxybenzophenone (1.2 equiv, 9.6 mmol, 
1.90 g), K2CO3 (1.3 equiv, 10.4 mmol, 1.44 g), and anhydrous dimethylformamide solvent (DMF, 150 
mL). The reaction mixture was stirred at 120 oC in a preheated oil bath overnight. After the reaction, the 
reaction was washed with water (~500 mL) and ethyl acetate (EtOAc, ~100 mL). The organic fraction 
was further washed with dilute NaOH solution (~1 M (aq), ~50 mL) followed by saturated NaCl solution 
(~50 mL). The organic fraction was dried with anhydrous MgSO4 and then concentrated in vacuo with 
the aid of a rotary evaporator. The residue was recrystallized using CH2Cl2 and hexanes as solvents to 
afford the title compound as a white amorphous solid (1.86 g, 5.83 mmol, 73%). 1H NMR (400 MHz, 
CDCl3): δ 8.26 (d, J = 9.2 Hz, 2 H), 7.91 (d, J = 8.7 Hz, 2 H), 7.81 (d, J = 7.7 Hz, 2 H), 7.62 (d, J = 7.4 
Hz, 1 H), 7.50 (d, J = 7.3 Hz, 2 H), 7.17 (d, J = 8.7 Hz, 2 H), 7.14 (d, J = 9.2 Hz, 2 H). 13C NMR (100 
MHz, CDCl3): δ 195.3, 161.9, 158.7, 143.5, 137.5, 134.2, 132.7, 132.6, 130.0, 128.5, 126.2, 119.5, 
118.5. HRMS (ESI): Calcd for C19H14NO4 [M+H]: 320.0923; Found: 320.0922. Mp: 121-123 
oC. Rf  = 
0.66 (EtOAc : petroleum ether = 1:2). IR (neat, cm-1): 1646, 1586, 1510, 1350, 1283, 1252, 1166, 843.  
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 Amide Synthesis via Mn-Mediated Reductive Transamidation of Tertiary 
Amides. 
 
 
Manganese-Mediated Reductive Transamidation of Tertiary Amide with Nitroarene (General 
Procedure C). An oven-dried 20 mL Schlenk tube equipped with a Teflon-coated magnetic stir bar was 
sequentially charged with manganese powder (Mn, 5 equiv., 2.5 mmol, 138 mg), tertiary amide (1 
equiv., 0.50 mmol), nitroarene (1.5 equiv., 0.75 mmol), and 1,10-phenanthroline (phen, 10 mol %, 9.0 
mg). The tube was degassed in vacuo and then backfilled with argon gas for three times. N-
Methylpyrrolidone solvent (NMP, 1.0 mL) followed by iodotrimethylsilane (TMSI, 1 equiv., 0.50 
mmol, 71 μL) were then transferred into the reaction mixture under the argon atmosphere. The resulting 
mixture was stirred at 120 oC in a preheated oil bath for 24 h. After the reaction, the reaction mixture 
was cooled down to room temperature. The reaction mixture was diluted with ethyl acetate (EtOAc, ~50 
mL), and the organic fraction was further acidified with HCl solution (~1 M (aq), ~10 mL), neutralized 
with KOH solution (~1 M (aq), ~30 mL), washed with saturated NaCl solution, dried with anhydrous 
MgSO4, and then concentrated in vacuo with the aid of a rotary evaporator. The residue was purified by 
flash column chromatography using a solvent mixture (hexanes, EtOAc, Et3N) as an eluent to afford the 
purified amide product.  
 
 
Manganese-Mediated Reductive Transamidation of Tertiary Amide with Nitroarene (General 
Procedure D). In a nitrogen-filled glove box, an oven-dried 30 mL re-sealable screw-cap test tube 
equipped with a Teflon-coated magnetic stir bar was sequentially charged with manganese powder (Mn, 
5 equiv., 1.75 mmol, 96 mg), tertiary amide (1 equiv., 0.35 mmol), nitroarene (1.5 equiv., 0.525 mmol), 
1,10-phenanthroline (phen, 10 mol %, 6.3 mg), N-methylpyrrolidone solvent (NMP, 0.7 mL), and 
iodotrimethylsilane (TMSI, 1 equiv., 50 μL). The resulting mixture was stirred at 120 oC in a preheated 
oil bath for 24 h. After the reaction, the reaction mixture was cooled down to room temperature. The 
reaction mixture was acidified with saturated NH4Cl solution (~5 mL) and then neutralized with 
saturated NaHCO3 solution (~10 mL). The crude product in the aqueous fraction was extracted with 
ethyl acetate (EtOAc, ~20 mL). The aqueous fraction was further washed with EtOAc (3 x ~10 mL). 
The combined organic fractions were concentrated in vacuo with the aid of a rotary evaporator. The 
residue was purified by preparative thin-layer chromatography (TLC) using a solvent mixture (hexanes, 
EtOAc, CH2Cl2) as an eluent to afford the purified amide product.  
 
 
Note: The main difference of procedures C and D is the conditions for inert atmosphere. Procedure C 
useed argon as the protective gas for reactions in Schlenk tubes, while procedure D used glovebox filled 
with N2.   
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N-(4-(1H-Pyrrol-1-yl)phenyl)benzamide (3a).34 Following the general procedure C, the title 
compound was prepared using N,N-diphenylbenzamide (1 equiv, 0.50 mmol, 137 mg) and 1-(4-
nitrophenyl)-1H-pyrrole (1.5 equiv, 0.75 mmol, 141 mg) using hexanes/EtOAc/NEt3 (90:10:1) and then 
hexanes/EtOAc/NEt3 (80:20:1) as an eluent to afford the title compound as a brown amorphous solid 
(94 mg, 72%). 1H NMR (400 MHz, DMSO-d6): δ 10.34 (s, 1 H), 7.98 (d, J = 6.7 Hz, 2 H), 7.88 (d, J = 
8.0 Hz, 2 H), 7.62-7.51 (m, 5 H), 7.34 (s, 2 H), 6.26 (s, 2 H). 13C NMR (100 MHz, DMSO-d6): δ 165.4, 
136.5, 135.7, 134.8, 131.6, 128.4, 127.6, 121.3, 119.5, 118.8, 110.2. HRMS (ESI): Calcd for C17H15N2O 
[M+H]: 263.1184; Found: 263.1190.  
 
 
 
 
N-(4-(N,N-diethylsulfamoyl)phenyl)benzamide (3b). Following the general procedure C, the title 
compound was prepared using N,N-diphenylbenzamide (1 equiv, 0.50 mmol, 194 mg) and N,N-diethyl-
4-nitrobenzenesulfonamide (1.5 equiv, 0.75 mmol, 141 mg) using hexanes/EtOAc/NEt3 (90:10:1) and 
then hexanes/EtOAc/NEt3 (70:30:1) as an eluent to afford the title compound as an off-white amorphous 
solid (112 mg, 67%). 1H NMR (600 MHz, CDCl3): δ 8.84 (s, 1 H), 7.89 (d, J = 7.6 Hz, 2 H), 7.83 (d, J 
= 8.5 Hz, 2 H), 7.67 (d, J = 8.4 Hz, 2 H), 7.52 (t, J = 7.3 Hz, 1 H), 7.41 (d, J = 7.6 Hz, 2 H), 3.18 (q, J 
= 7.1 Hz, 4 H), 1.09 (d, J = 7.2 Hz, 6 H). 13C NMR (150 MHz, CDCl3): δ 166.5, 142.1, 134.9, 134.2, 
132.3, 128.8, 128.0, 127.4, 120.2, 42.1, 14.2. HRMS (ESI): Calcd for C17H21N2O3S [M+H]: 333.1273; 
Found: 333.1265. Mp: 104-106 oC. Rf  = 0.33 (EtOAc : petroleum ether = 1:2). IR (neat, cm-1): 2360, 
1666, 1593, 1523, 1399, 1329, 1151, 1021, 938, 832. 
 
 
 
 
N-(3-chlorophenyl)benzamide (3c).35 Following the general procedure C, the title compound was 
prepared using N,N-diphenylbenzamide (1 equiv, 0.50 mmol, 137 mg) and 3-chloronitrobenzene (1.5 
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equiv, 0.75 mmol, 118 mg) using hexanes/EtOAc/NEt3 (90:10:1) and then hexanes/EtOAc/NEt3 
(80:20:1) as an eluent to afford the title compound as an off-white amorphous solid (93 mg, 80%). 1H 
NMR (400 MHz, CDCl3): δ 7.95 (s, 1 H), 7.84 (d, J = 7.4 Hz, 2 H), 7.77 (s, 1 H), 7.55 (t, J = 7.3 Hz, 1 
H), 7.49-7.45 (ovrlp, 3 H), 7.27 (t, J = 8.1 Hz, 1 H), 7.12 (d, J = 7.9 Hz, 1 H). 13C NMR (100 MHz, 
CDCl3): δ 166.4, 139.2, 134.6, 134.5, 132.1, 130.0, 128.8, 127.2, 124.6, 120.7, 118.6.  
 
 
 
 
N-(3-Cyano-4-methylphenyl)benzamide (3d). Following the general procedure C, the title compound 
was prepared using N,N-diphenylbenzamide (1 equiv, 0.50 mmol, 137 mg) and 2-methyl-5-
nitrobenzonitrile (1.5 equiv, 0.75 mmol, 122 mg) using hexanes/EtOAc/NEt3 (90:10:1) and then 
hexanes/EtOAc/NEt3 (30:70:1) as an eluent to afford the title compound as a pale-yellow amorphous 
solid (50 mg, 42%). 1H NMR (400 MHz, CD2Cl2): δ 8.05 (s, 1 H), 8.03 (d, J = 2.0 Hz, 1 H), 7.87 (d, J 
= 7.3 Hz, 2 H), 7.71 (dd, J = 8.4 Hz, J = 2.1 Hz, 1 H), 7.58 (t, J = 7.4 Hz, 1 H), 7.50 (t, J = 7.7 Hz, 2 H), 
7.32 (d, J = 8.4 Hz, 1 H), 2.51 (s, 3 H). 13C NMR (100 MHz, CD2Cl2): δ 166.0, 138.1, 136.8, 134.8, 
132.5, 131.2, 129.2, 127.4, 124.8, 123.9, 118.1, 113.5, 20.1. HRMS (ESI): Calcd for C15H13N2O [M+H]: 
237.1028; Found: 237.1040. Mp: 174-176 oC. Rf  = 0.50 (EtOAc : petroleum ether = 1:2). IR (neat, cm-
1): 3344, 2363, 2223, 1652, 1580, 1527, 1445, 1401, 1311, 1253, 833. 
  
 
 
 
N-(4-aminophenyl)benzamide (3e).36 Following the general procedure C, the title compound was 
prepared using N,N-diphenylbenzamide (1 equiv, 0.50 mmol, 137 mg) and 4-nitroaniline (1.5 equiv, 
0.75 mmol, 104 mg) using hexanes/EtOAc/NEt3 (90:10:1) and then hexanes/EtOAc/NEt3 (20:80:1) as 
an eluent to afford the title compound as a brown amorphous solid (81 mg, 77%). 1H NMR (400 MHz, 
CDCl3): δ 7.85 (d, J = 6.8 Hz, 2 H), 7.67 (s, 1 H), 7.55 (t, J = 6.8 Hz, 1 H), 7.47 (t, J = 7.2 Hz, 2 H), 
7.40 (d, J = 7.6 Hz, 2 H), 6.69 (d, J = 8.0 Hz, 2 H), 3.63 (br s, 2 H). 13C NMR (150 MHz, CDCl3): δ 
165.7, 143.7, 135.3, 131.6, 129.4, 128.8, 127.1, 122.5, 115.6.  
   
 
 
 S16   
 
N-(4-(tert-Butyl)phenyl)cyclobutanecarboxamide (3f). Following the general procedure C, the title 
compound was prepared using N,N-diphenylcyclobutanecarboxamide (1 equiv, 0.50 mmol, 126 mg) and 
1-(tert-butyl)-4-nitrotoluene (1.5 equiv, 0.75 mmol, 127 μL) using hexanes/EtOAc/NEt3 (90:10:1) and 
then hexanes/EtOAc/NEt3 (80:20:1) as an eluent to afford the title compound as an off-white amorphous 
solid (89 mg, 77%). 1H NMR (400 MHz, CD2Cl2): δ 7.43 (d, J = 8.2 Hz, 2 H), 7.33 (d, J = 8.4 Hz, 2 
H), 7.16 (s, 1 H), 3.14 (quint, J = 8.4 Hz, 1 H), 2.39-2.30 (m, 2 H), 2.23-2.15 (m, 2 H), 2.05-1.96 (m, 1 
H), 1.92-1.81 (m, 1 H), 1.30 (s, 9 H). 13C NMR (100 MHz, CD2Cl2): δ 173.4, 147.3, 136.2, 126.1, 119.9, 
41.2, 34.6, 31.5, 25.7, 18.4. HRMS (ESI): Calcd for C15H22NO [M+H]: 232.1701; Found: 232.1713. 
Mp: 133-135 oC. Rf  = 0.68 (EtOAc : petroleum ether = 1:2). IR (neat, cm-1): 2959, 1658, 1597, 1529, 
1494, 1312, 1258, 826.  
 
 
 
 
N-(Benzo[d][1,3]dioxol-5-yl)cyclopentanecarboxamide (3g). Following the general procedure C, the 
title compound was prepared using N,N-diphenylcyclopentanecarboxamide (1 equiv, 0.50 mmol, 133 
mg) and 5-nitrobenzo[d][1,3]dioxole (1.5 equiv, 0.75 mmol, 125 mg) using hexanes/EtOAc/NEt3 
(90:10:1) and then hexanes/EtOAc/NEt3 (70:30:1) as an eluent to afford the title compound as a pale 
brown amorphous solid (70 mg, 60%). 1H NMR (400 MHz, CDCl3): δ 7.26 (s, 1 H), 7.09 (s, 1 H), 6.78 
(d, J = 7.5 Hz, 1 H), 6.72 (d, J = 8.2 Hz, 1 H), 5.93 (s, 2 H), 2.63 (quint, J = 7.9 Hz, 1 H), 1.99-1.74 (m, 
6 H), 1.63-1.54 (m, 2 H). 13C NMR (100 MHz, CD2Cl2): δ 174.8, 148.1, 144.3, 133.3, 113.2, 108.2, 
103.0, 101.8, 47.1, 30.9, 26.4. HRMS (ESI): Calcd for C13H16NO3 [M+H]: 234.1130; Found: 234.1136. 
Mp: 150-152 oC. Rf  = 0.53 (EtOAc : petroleum ether = 1:2). IR (neat, cm-1): 3266, 2363, 1646, 1534, 
1504, 1489, 1446, 1215, 1038, 932.  
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N-(4-methoxyphenyl)oleamide (3h).37 Following the general procedure C, the title compound was 
prepared using N,N-diphenyloleamide (1 equiv, 0.50 mmol, 217 mg) and 4-nitroanisole (1.5 equiv, 0.75 
mmol, 115 mg) using hexanes/EtOAc/NEt3 (90:10:1) and then hexanes/EtOAc/NEt3 (70:30:1) as an 
eluent to afford the title compound as a brown amorphous solid (176 mg, 91%). 1H NMR (400 MHz, 
CDCl3): δ 7.84 (s, 1 H), 7.40 (d, J = 8.6 Hz, 2 H), 6.80 (d, J = 8.7 Hz, 2 H), 5.37-5.31 (m, 2 H), 3.76 (s, 
3 H), 2.30 (t, J = 7.4 Hz, 2 H), 2.08-1.92 (m, 4 H), 1.68 (quint, J = 6.0 Hz, 2 H), 1.40-1.20 (m, 20 H), 
0.88 (t, J = 6.6 Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 171.8, 156.3, 131.3, 130.0, 129.8, 122.0, 
114.0, 55.5, 37.5, 32.0, 29.83, 29.80, 29.6, 29.42, 29.39, 29.2, 27.3, 27.2, 25.9, 22.8, 14.2 (21 carbon 
signals were observed out of expected 23 carbon signals) 
 
 
 
 
4-(tert-Butyl)-N-(4-(tert-butyl)phenyl)benzamide (3i). Following the general procedure D, the title 
compound was prepared using 4-(tert-butyl)-N,N-di-p-tolylbenzamide (1 equiv, 0.35 mmol, 125 mg) 
and 1-tert-butyl-4-nitrobzenene (1.5 equiv, 0.525 mmol, 94 mg) using hexanes/EtOAc/CH2Cl2 (80:15:5) 
as an eluent to afford the title compound as a brown amorphous solid (57 mg, 52%). 1H NMR (400 
MHz, CDCl3): δ 7.94 (s, 1 H), 7.79 (d, J = 8.5 Hz, 2 H), 7.56 (d, J = 8.5 Hz, 2 H), 7.45  (d, J = 8.4 Hz, 
2 H), 7.36 (d, J = 8.6 Hz, 2 H), 1.33 (s, 9 H), 1.31 (s, 9 H). 13C NMR (100 MHz, CDCl3): δ 165.8, 155.3, 
147.5, 135.6, 132.3, 127.0, 126.0, 125.8, 120.1, 35.1, 34.5, 31.5, 31.3. HRMS (ESI): Calcd for 
C21H28NO [M+H]: 310.2171; Found: 310.2169. Mp: 151-153 
oC. Rf  = 0.89 (EtOAc : petroleum ether 
= 1:2). 
 
 
 
 
N-Phenylbenzamide (3j).38 Following the general procedure C, the title compound was prepared using 
N-methyl-N-phenylbenzamide (1 equiv, 0.50 mmol, 106 mg) and nitrobenzene (1.5 equiv, 0.75 mmol, 
92 mg) using hexanes/EtOAc/NEt3 (90:10:1) as an eluent to afford the title compound as a white  
amorphous solid (74 mg, 75%). 1H NMR (400 MHz, CDCl3): δ 7.97 (s, 1 H), 7.85 (d, J = 7.4 Hz, 2 H), 
7.64 (d, J = 7.9 Hz, 2 H), 7.53 (t, J = 7.3 Hz, 1 H), 7.45 (d, J = 7.6 Hz, 2 H), 7.35 (d, J = 7.7 Hz, 2 H), 
7.14 (t, J = 7.4 Hz, 1 H). 13C NMR (100 MHz, CDCl3): δ 166.0, 138.1, 135.1, 131.9, 129.2, 128.9, 
127.2, 124.1, 120.4.  
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N-(6-Methoxypyridin-3-yl)benzamide (3k).39 Following the general procedure D, the title compound 
was prepared using N-methyl-N-phenylbenzamide (1 equiv, 0.35 mmol, 74 mg) and 2-methoxy-5-
nitropridine (1.5 equiv, 0.525 mmol, 81 mg) using hexanes/EtOAc/CH2Cl2 (20:75:5) as an eluent to 
afford the title compound as a brown amorphous solid (70 mg, 88%). 1H NMR (400 MHz, CDCl3): δ 
8.26 (s, 1 H), 8.02 (d, J = 8.8 Hz, 1 H), 7.90-7.85 (m, 3 H), 7.56 (d, J = 7.3 Hz, 1 H), 7.48 (d, J = 7.4 
Hz, 2 H), 6.77 (d, J = 8.7 Hz, 1 H), 3.93 (s, 3 H). 13C NMR (100 MHz, CDCl3): 166.2, 161.4, 139.2, 
134.5, 132.9, 132.2, 128.9, 128.7, 127.2, 110.9, 53.8. HRMS (ESI): Calcd for C13H13N2O2 [M+H]: 
229.0972; Found: 229.0974.  
 
 
 
 
N-(2,4-dimethylphenyl)-4-methoxybenzamide (3l).34 Following the general procedure C, the title 
compound was prepared using 4-methoxy-N-methyl-N-phenylbenzamide (1 equiv, 0.50 mmol, 121 mg) 
and 2,4-dimethyl-1-nitrobenzene (1.5 equiv, 0.75 mmol, 113 mg) using hexanes/EtOAc/Et3N (90:10:1) 
and then hexanes/EtOAc/Et3N (80:20:1) as an eluent to afford the title compound as an off-white 
amorphous solid (75 mg, 59%). 1H NMR (400 MHz, CD2Cl2): δ 7.84 (d, J = 8.8 Hz, 2 H), 7.66-7.60 
(m, 2 H), 7.06 (s, 1 H), 7.04 (d, J = 8.2 Hz, 1 H), 6.98 (d, J = 8.8 Hz, 2 H), 3.87 (s, 3 H), 2.32 (s, 3 H), 
2.27 (s, 3 H). 13C NMR (100 MHz, CD2Cl2): δ 165.4, 162.8, 135.5, 133.9, 131.5, 130.8, 129.3, 127.6, 
127.5, 124.1, 114.2, 55.9, 21.0, 18.0. HRMS (ESI): Calcd for C16H18NO2 [M+H]: 256.1338; Found: 
256.1353. 
 
 
 
N-(3-methoxy-4-methylphenyl)-4-(trifluoromethyl)benzamide (3m).34  
 
Reaction (1): Following the general procedure C, the title compound was prepared using N-methyl-N-
phenyl-4-(trifluoromethyl)benzamide (1 equiv, 0.50 mmol, 140 mg) and 3-methoxy-4-
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methylnitrobenzene (1.5 equiv, 0.75 mmol, 125 mg) using hexanes/EtOAc/Et3N (90:10:1) and then 
hexanes/EtOAc/Et3N (80:20:1) as an eluent to afford the title compound as a pale-brown amorphous 
solid (135 mg, 87%). 1H NMR (400 MHz, CDCl3): δ 7.96 (d, J = 8.0 Hz, 2 H), 7.87 (s, 1 H), 7.73 (d, J 
= 8.2 Hz, 2 H), 7.45 (s, 1 H), 7.09 (d, J = 7.9 Hz, 1 H), 6.91 (dd, J = 7.8 Hz, J = 1.3 Hz, 1 H), 3.85 (s, 3 
H), 2.20 (s, 3 H). 13C NMR (100 MHz, CDCl3): δ 164.6, 158.2, 138.5, 136.6, 133.5 (q, 2JCF = 32.6 Hz), 
130.7, 127.6, 125.9 (q, 3JCF = 3.7 Hz), 123.74 (q, 
1JCF = 271.2 Hz), 123.67, 112.0, 103.4, 55.5, 15.9.  
 
 
 
 
Reaction (2): Following the general procedure C, the title compound was prepared using morpholino(4-
(trifluoromethyl)phenyl)methanone (1 equiv, 0.50 mmol, 130 mg) and 3-methoxy-4-
methylnitrobenzene (1.5 equiv, 0.75 mmol, 125 mg) using hexanes/EtOAc/Et3N (90:10:1) and then 
hexanes/EtOAc/Et3N (80:20:1) as an eluent to afford the title compound as an off-white amorphous 
solid (109 mg, 71%). Spectral and analytical data were identical to those reported for the same 
compound above.  
 
 
 
 
N-(3-(trifluoromethyl)phenyl)-2-naphthamide (3n).40 Following the general procedure C, the title 
compound was prepared using N-methyl-N-phenyl-2-naphthamide (1 equiv, 0.50 mmol, 131 mg) and 3-
nitrobenzotrifluoride (1.5 equiv, 0.75 mmol, 143 mg) using hexanes/EtOAc/Et3N (90:10:1) as an eluent 
to afford the title compound as a pale-brown amorphous solid (79 mg, 50%). 1H NMR (400 MHz, 
CDCl3): δ 8.33 (s, 1 H), 8.27 (s, 1 H), 7.98 (s, 1 H), 7.93-7.85 (m, 5 H), 7.60-7.52 (m, 2 H), 7.47 (t, J = 
8.0 Hz, 1 H), 7.40 (d, J = 7.8 Hz, 1 H). 13C NMR (100 MHz, CDCl3): δ 166.2, 138.7, 135.1, 132.7, 
131.7, 131.6 (q, 2JCF = 32.3 Hz), 129.8, 129.1, 129.0, 128.3, 128.1, 128.0, 127.8, 127.2 (q, 
1JCF = 270.6 
Hz), 123.52, 123.46 (q, 4JCF = 0.8 Hz), 121.2 (q, 
3JCF = 3.8 Hz), 117.1 (q, 
3JCF = 4.0 Hz).   
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N-(4-((4-methoxyphenyl)amino)phenyl)nicotinamide (3o).41 Following the general procedure C, the 
title compound was prepared using N-methyl-N-phenylnicotinamide (1 equiv, 0.70 mmol, 147 mg), 4-
methoxy-N-(4-nitrophenyl)aniline (1.5 equiv, 1.05 mmol, 256 mg), phen (10 mol %, 12.6 mg), Mn (5 
equiv, 3.5 mmol, 195 mg), NMP (1.4 mL), and TMSI (1 equiv, 0.70 mmol, 99 μL) using 
hexanes/EtOAc/Et3N (60:40:1) and then hexanes/EtOAc (20:80) as an eluent to afford the title 
compound as an deep-brown amorphous solid (79 mg, 50%). 1H NMR (600 MHz, DMSO-d6): δ 10.25 
(s, 1 H), 9.10 (s, 1 H), 8.74 (d, J = 3.8 Hz, 1 H), 8.28 (d, J = 7.9 Hz, 1 H), 7.84 (s, 1 H), 7.59-7.53 (m, 3 
H), 7.03 (d, J = 8.8 Hz, 2 H), 6.95 (d, J = 8.8 Hz, 2 H), 6.86 (d, J = 8.8 Hz, 2 H), 3.71 (s, 3 H). 13C NMR 
(150 MHz, DMSO-d6): δ 163.3, 153.5, 151.9, 148.7, 141.5, 136.6, 135.3, 130.8, 130.2, 123.5, 122.0, 
119.7, 115.2, 114.6, 55.2.  
 
 
 
 
N-(p-Tolyl)furan-2-carboxamide (3p).42 Following the general procedure C, the title compound was 
prepared using N-methyl-N-phenylfuran-2-carboxamide (1 equiv, 0.50 mmol, 101 mg) and 4-
nitrotoluene (1.5 equiv, 0.75 mmol, 103 mg) using hexanes/EtOAc/Et3N (90:10:1) as an eluent to afford 
the title compound as a brown amorphous solid (85 mg, 81%). 1H NMR (400 MHz, CD2Cl2): δ 8.07 (s, 
1 H), 7.54 (dd, J = 1.6 Hz, J = 0.7 Hz, 1 H), 7.52 (d, J = 8.4 Hz, 2 H), 7.19-7.16 (m, 3 H), 6.57 (dd, J = 
3.5 Hz, J = 1.8 Hz, 1 H), 2.33 (s, 3 H). 13C NMR (100 MHz, CD2Cl2): δ 156.3, 148.5, 144.7, 135.4, 
134.6, 129.9, 120.4, 115.1, 112.8, 21.0.   
 
  
 
 
N-(4-(tert-butyl)phenyl)benzamide (3q).43 Following the general procedure C, the title compound was 
prepared using N-ethyl-N-phenylbenzamide (1 equiv, 0.50 mmol, 113 mg) and 1-tert-butyl-4-
nitrobenzene (1.5 equiv, 0.75 mmol, 128 μL) using hexanes/EtOAc/Et3N (95:5:1) as an eluent to afford 
the title compound as a brown amorphous solid (65 mg, 51%). 1H NMR (400 MHz, CD2Cl2): δ 7.96 (s, 
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1 H), 7.86 (d, J = 7.2 Hz, 2 H), 7.58-7.53 (m, 3 H), 7.49 (t, J = 7.1 Hz, 2 H), 7.40 (d, J = 8.6 Hz, 2 H), 
1.33 (s, 9 H). 13C NMR (100 MHz, CD2Cl2): δ 165.9, 147.9, 135.9, 135.6, 132.1, 129.1, 127.3, 126.2, 
120.4, 34.7, 31.5.   
 
 
 
 
N-(4-methoxyphenyl)-4-(trifluoromethoxy)benzamide (3r). Following the general procedure C, the 
title compound was prepared using N-butyl-N-phenyl-4-(trifluoromethoxy)benzamide (1 equiv, 0.50 
mmol, 169 mg) and 4-nitroanisole (1.5 equiv, 0.75 mmol, 115 mg) using hexanes/EtOAc/Et3N (90:10:1) 
as an eluent to afford the title compound as an off-white amorphous solid (111 mg, 71%). 1H NMR (400 
MHz, CDCl3): δ 7.91 (d, J = 8.2 Hz, 2 H), 7.70 (s, 1 H), 7.52 (d, J = 8.2 Hz, 2 H), 7.31 (d, J = 8.1 Hz, 2 
H), 6.91 (d, J = 8.6 Hz, 2 H), 3.82 (s, 3 H). 13C NMR (100 MHz, DMSO-d6): δ 163.9, 155.7, 150.4, 
134.2, 132.0, 129.9, 122.0, 120.0 (q,1JCF = 255.5 Hz), 120.7, 113.8, 55.2. 19F NMR (376 MHz, CDCl3, 
CFCl3 as external standard): δ -57.7. HRMS (ESI): Calcd for C15H13F3NO3 [M+H]: 312.0848; Found: 
312.0859. Mp: 197-199 oC. Rf  = 0.60 (EtOAc : petroleum ether = 1:2). IR (neat, cm-1): 3440, 2362, 1644, 
1515, 1209, 1160, 1104, 1031, 899, 863, 825.    
  
 
 
N-benzyl-N-phenyl-4-(trifluoromethyl)benzamide (3s).44  
 
Reaction 1: Following the general procedure C, the title compound was prepared using N-benzyl-N-
phenyl-4-(trifluoromethyl)benzamide (1 equiv, 0.50 mmol, 178 mg) and 4-nitroanisole (1.5 equiv, 0.75 
mmol, 115 mg) using hexanes/EtOAc/Et3N (90:10:1) as an eluent to afford the title compound as an off-
white amorphous solid (87 mg, 59%). 1H NMR (600 MHz, DMSO-d6): δ 10.3 (s, 1 H), 8.14 (d, J = 7.9 
Hz, 2 H), 7.90 (d, J = 8.0 Hz, 2 H), 7.68 (d, J = 8.6 Hz, 2 H), 6.94 (d, J = 8.8 Hz, 2 H), 3.75 (s, 3 H). 
13C NMR (150 MHz, DMSO-d6): δ 163.9, 155.8, 138.8, 131.8, 131.2 (q, 2JCF = 31.6 Hz), 128.4, 125.3 
(q, 3JCF = 3.7 Hz), 123.9 (q, 
1JCF = 270.9 Hz), 122.0, 113.8, 55.2. 
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Reaction 2: Following the general procedure C, the title compound was prepared using N,N-dimethyl-
4-(trifluoromethyl)benzamide (1 equiv, 0.50 mmol, 109 mg), 4-nitroanisole (3 equiv, 1.5 mmol, 231 
mg), phen (20 mol %, 18 mg), Mn (10 equiv, 276 mg), and TMSI (2 equiv, 143 μL) using 
hexanes/EtOAc/Et3N (90:10:1) as an eluent to afford the title compound as a brown amorphous solid 
(69 mg, 47%). Spectral and analytical data were identical to those reported for the same compound 
above. 
 
 
 
N-(4-methoxyphenyl)benzamide (3t).45 
 
Reaction 1: Following the general procedure C, the title compound was prepared using N-(2-
hydroxyethyl)-N-phenylbenzamide (1 equiv, 0.50 mmol, 121 mg) and 4-nitroanisole (1.5 equiv, 0.75 
mmol, 115 mg) using hexanes/EtOAc/Et3N (90:10:1) and then hexanes/EtOAc/Et3N (80:20:1) as an 
eluent to afford the title compound as a pale brown amorphous solid (75 mg, 66%). 1H NMR (400 MHz, 
CDCl3): δ 7.87-7.83 (m, 3 H), 7.55-7.51 (m, 3 H), 7.46 (t, J = 7.5 Hz, 2 H), 6.89 (d, J = 8.8 Hz, 2 H), 
3.81 (s, 3 H). 13C NMR (100 MHz, CDCl3): δ 165.8, 156.7, 135.1, 131.8, 131.1, 128.9, 127.1, 122.3, 
114.3, 55.6. 
 
 
Reaction 2: Following the general procedure C, the title compound was prepared using 
morpholino(phenyl)methanone (1 equiv, 0.50 mmol, 96 mg) and 4-nitroanisole (1.5 equiv, 0.75 mmol, 
115 mg) using hexanes/EtOAc/Et3N (90:10:1) and then hexanes/EtOAc/Et3N (80:20:1) as an eluent to 
afford the title compound as an off-white amorphous solid (61 mg, 53%). Spectral and analytical data 
were identical to those reported for the same compound above. 
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Reaction 3: Following the general procedure C, the title compound was prepared using 1-(4-
benzoylpiperazin-1-yl)-2,2-dimethylpropan-1-one (1 equiv, 0.50 mmol, 137 mg), and 4-nitroanisole 
(1.5 equiv, 0.75 mmol, 115 mg) using hexanes/EtOAc/Et3N (90:10:1) and then hexanes/EtOAc/Et3N 
(80:20:1) as an eluent to afford the title compound as an off-white amorphous solid (61 mg, 59%). 
Spectral and analytical data were identical to those reported for the same compound above. 
 
 
Reaction 4: Following the general procedure C, the title compound was prepared using phenyl(4-
((trifluoromethyl)sulfonyl)piperazin-1-yl)methanone (1 equiv, 0.50 mmol, 161 mg) and 4-nitroanisole 
(1.5 equiv, 0.75 mmol, 115 mg) for 2 days using hexanes/EtOAc/Et3N (90:10:1) and then 
hexanes/EtOAc/Et3N (80:20:1) as an eluent to afford the title compound as an off-white amorphous 
solid (80 mg, 70%). Spectral and analytical data were identical to those reported for the same compound 
above. 
 
 
 
 
N-(3-methoxy-4-methylphenyl)benzamide (3u).40 Following the general procedure C, the title 
compound was prepared using N-(4-fluorophenyl)-N-methylbenzamide (1 equiv, 0.50 mmol, 115 mg) 
and 3-methoxy-4-methylnitrobenzene (1.5 equiv, 0.75 mmol, 125 mg) using hexanes/EtOAc/Et3N 
(90:10:1) and then hexanes/EtOAc/Et3N (80:20:1) as an eluent to afford the title compound as a brown 
amorphous solid (95 mg, 78%). 1H NMR (400 MHz, CDCl3): δ 8.22 (s, 1 H), 7.83 (d, J = 7.6 Hz, 2 H), 
7.50-7.44 (m, 2 H), 7.39 (t, J = 7.5 Hz, 2 H), 7.03 (d, J = 8.0 Hz, 1 H), 6.93 (d, J = 7.4 Hz, 1 H), 3.76 
(s, 3 H), 2.17 (s, 3 H). 13C NMR (100 MHz, CDCl3): δ 166.0, 158.0, 137.1, 135.1, 131.7, 130.5, 128.7, 
127.1, 122.9, 111.9, 103.3, 55.3, 15.9.  
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4-Fluoro-N-(4-(phenylamino)phenyl)benzamide (3v).34 Following the general procedure D, the title 
compound was prepared using (4-fluorophenyl)(indolin-1-yl)methanone (1 equiv, 0.35 mmol, 84 mg) 
and 4-nitro-N-phenylaniline (1.5 equiv, 0.525 mmol, 112 mg) using hexanes/EtOAc/CH2Cl2 (60:35:5) 
as an eluent to afford the title compound as a brown amorphous solid (93 mg, 85%). 1H NMR (400 
MHz, DMSO-d6): δ 10.12 (s, 1 H), 8.09 (s, 1 H), 8.03 (dd, 3JHH = 8.6 Hz, 4JHF = 5.7 Hz, 2 H), 7.63 (d, 
J = 8.0 Hz, 2 H), 7.35 (dd, 3JHH = 8.3 Hz, 
3JHF = 8.3 Hz, 2 H), 7.21 (t, J = 7.0 Hz, 2 H), 7.09-7.03 (m, 4 
H), 6.78 (t, J = 6.7 Hz, 1 H). 13C NMR (100 MHz, DMSO-d6): δ 163.93 (d, 1JCF = 246.6 Hz), 163.90, 
143.9, 139.4, 131.7, 131.5 (d, 4JCF = 2.2 Hz), 130.2 (d, 
3JCF = 8.7 Hz), 129.1, 121.8, 119.1, 117.4, 116.0, 
115.2 (d, 2JCF = 21.7). HRMS (ESI): Calcd for C19H16FN2O [M+H]: 307.1247; Found: 307.1247.  
 
 
 
 
N-(4-(9H-Carbazol-9-yl)phenyl)-4-methylbenzamide (3w).40 Following the general procedure C, the 
title compound was prepared using indolin-1-yl(p-tolyl)methanone (1 equiv, 0.50 mmol, 119 mg) and 
9-(4-nitrophenyl)-9H-carbazole (1.5 equiv, 0.75 mmol, 216 mg) using hexanes/EtOAc/Et3N (90:10:1) 
and then hexanes/EtOAc/Et3N (70:30:1) as an eluent to afford the title compound as a pale-brown 
amorphous solid (154 mg, 82%). 1H NMR (400 MHz, DMSO-d6): δ 10.45 (s, 1 H), 8.25 (d, J = 7.6 Hz, 
2 H), 8.10 (d, J = 8.5 Hz, 2 H), 7.94 (d, J = 7.8 Hz, 2 H), 7.60 (d, J = 8.5 Hz, 2 H), 7.44 (t, J = 7.6 Hz, 
2 H), 7.40-7.36 (m, 4 H), 7.29 (t, J = 7.3 Hz, 2 H), 2.41 (s, 3 H). 13C NMR (100 MHz, DMSO-d6): δ 
165.6, 141.7, 140.3, 138.7, 132.0, 131.9, 129.0, 127.8, 127.0, 126.2, 122.6, 121.6, 120.5, 119.9, 109.6, 
21.0.  
 
 
 
 
4-(Dimethylamino)-N-(4-(p-tolyloxy)phenyl)benzamide (3x). Following the general procedure C, the 
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title compound was prepared using (4-(dimethylamino)phenyl)(indolin-1-yl)methanone (1 equiv, 0.50 
mmol, 133 mg) and 1-methyl-4-(4-nitrophenoxy)benzene (1.5 equiv, 0.75 mmol, 172 mg) using 
hexanes/EtOAc/Et3N (80:20:1) as an eluent to afford the title compound as a pale-brown amorphous 
solid (135 mg, 78%). 1H NMR (400 MHz, CD2Cl2): δ 8.08 (s, 1 H), 7.79 (d, J = 8.1 Hz, 2 H), 7.60 (d, 
J = 8.1 Hz, 2 H), 7.15 (d, J = 7.7 Hz, 2 H), 6.95 (d, J = 8.2 Hz, 2 H), 6.90 (d, J = 7.9 Hz, 2 H), 6.68 (d, 
J = 8.2 Hz, 2 H), 3.02 (s, 6 H), 2.33 (s, 3 H).  13C NMR (100 MHz, CD2Cl2): δ 165.9, 155.6, 154.0, 
153.1, 134.5, 133.1, 130.6, 129.0, 122.3, 121.5, 119.3, 118.9, 111.4, 40.3, 20.8. HRMS (ESI): Calcd for 
C22H23N2O2 [M+H]: 347.1760; Found: 347.1761. Mp: 141-143 
oC. Rf  = 0.46 (EtOAc : petroleum ether 
= 1:2). IR (neat, cm-1): 3490, 2919, 1728, 1637, 1611, 1501, 1261, 1226, 1193, 821.  
 
 
 
 
N-(4-(tert-Butyl)phenyl)-4-chlorobenzamide (3y).34 Following the general procedure D, the title 
compound was prepared using (4-chlorophenyl)(indolin-1-yl)methanone (1 equiv, 0.35 mmol, 90 mg) 
and 1-tert-butyl-4-nitrobenzene (1.5 equiv, 0.525 mmol, 94 mg) using hexanes/EtOAc/CH2Cl2 (70:25:5) 
as an eluent to afford the title compound as a white amorphous solid (81 mg, 81%). 1H NMR (400 MHz, 
CDCl3): δ 7.88 (s, 1 H), 7.78 (d, J = 8.4 Hz, 2 H), 7.53 (d, J = 8.5 Hz, 2 H), 7.41 (d, J = 8.4 Hz, 2 H), 
7.37 (d, J = 8.6 Hz, 2 H), 1.32 (s, 9 H). 13C NMR (100 MHz, CDCl3): δ 164.8, 148.0, 138.1, 135.2, 
133.6, 129.1, 128.6, 126.1, 120.3, 34.6, 31.5. HRMS (ESI): Calcd for C17H19ClNO [M+H]: 288.1155; 
Found: 288.1154.  
 
 
 
 
N-(4-methoxyphenyl)thiophene-2-carboxamide (3z).46  
(i) 0.5 mmol: Following the general procedure C, the title compound was prepared using indolin-1-
yl(thiophen-2-yl)methanone (1 equiv, 0.50 mmol, 115 mg) and 4-nitroanisole (1.5 equiv, 0.75 mmol, 
115 mg) using hexanes/EtOAc/Et3N (70:30:1) as an eluent to afford the title compound as an off-white 
amorphous solid (105 mg, 90%). 1H NMR (400 MHz, CDCl3): δ 7.92 (s, 1 H), 7.62 (d, J = 3.3 Hz, 1 
H), 7.51-7.48 (m, 3 H), 7.07 (dd, J = 4.8 Hz, J = 3.8 Hz, 1 H), 6.85 (d, J = 9.0 Hz, 2 H), 3.78 (s, 3 H). 
13C NMR (100 MHz, CDCl3): δ 160.2, 156.8, 139.5, 130.7, 130.6, 128.5, 127.9, 122.5, 114.3, 55.6.  
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(ii) 10 mmol: Following the general procedure C, the title compound was prepared using indolin-1-
yl(thiophen-2-yl)methanone (1 equiv, 10 mmol, 2.29 g), 4-nitroanisole (1.5 equiv, 15 mmol, 2.30 g), 
phen (10 mol %, 180 mg), Mn (5 equiv, 50 mmol, 2.75 g), NMP (20 mL), and TMSI (1 equiv, 10 mmol, 
1.43 mL) in a 100 mL round-bottom Schlenk flask for reaction time of 2 days using hexanes/EtOAc/Et3N 
(70:30:1) as an eluent to afford the title compound as an off-white amorphous solid (1.81 g, 78%). 
Spectral and analytical data were identical to those reported for the same compound above. 
 
 
 
 
(E)-3-Phenyl-N-(4-styrylphenyl)propanamide (3aa).40 Following the general procedure D, the title 
compound was prepared using 1-(indolin-1-yl)-3-phenylpropan-1-one (1 equiv, 0.35 mmol, 88 mg) and 
(E)-1-nitro-4-styrylbenzene (1.5 equiv, 0.525 mmol, 118 mg) for reaction time of 16 h using 
hexanes/EtOAc/CH2Cl2 (60:35:5) as an eluent to afford the title compound as a pale brown amorphous 
solid (86 mg, 75%). 1H NMR (400 MHz, CDCl3): δ 7.49 (d, J = 7.1 Hz, 2 H), 7.47-7.41 (m, 4 H), 7.36-
7.29 (m, 4 H), 7.27-7.21 (m, 4 H), 7.09 (s, 1 H), 7.05-7.02 (m, 2 H), 3.06 (t, J = 7.6 Hz, 2 H), 2.67 (t, J 
= 7.6 Hz, 2 H). 13C NMR (100 MHz, CDCl3): δ 170.4, 137.5, 137.3, 133.6, 128.8, 128.6, 128.1, 127.7, 
127.2, 126.6, 126.5, 120.1, 39.7, 31.7 (14 carbon signals were observed out of expected 17 carbon 
signals).   
 
 
 
 
1-(4-Fluorophenyl)undecan-2-one (3ab). Following the general procedure D, the title compound was 
prepared using 1-(indolin-1-yl)decan-1-one (1 equiv, 0.35 mmol, 96 mg) and 1-fluoro-4-nitrobenzene 
(1.5 equiv, 0.525 mmol, 74 mg) for reaction time of 16 h using hexanes/EtOAc/CH2Cl2 (80:15:5) as an 
eluent to afford the title compound as a brown amorphous solid (71 mg, 77%). 1H NMR (400 MHz, 
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CDCl3): δ 7.47 (dd, 3JHH = 7.7 Hz, 3JHF = 4.6 Hz, 2 H), 7.42 (s, 1 H), 6.99 (dd, 3JHH = 8.0 Hz, 3JHF = 8.0 
Hz, 2 H), 2.33 (t, J = 7.0 Hz, 2 H), 1.71 (quint, J = 7.4 Hz, 2 H), 1.41-1.18 (m, 12 H), 0.88 (t, J = 7.2 
Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 171.2, 159.4 (d, 1JCF = 241.6 Hz), 134.1 (d, 4JCF = 1.9 Hz), 
121.8 (d, 3JCF = 7.7 Hz), 115.7 (d, 
2JCF = 22.2 Hz), 37.8, 32.0, 29.6, 29.5, 29.42, 29.40, 25.8, 22.8, 14.2. 
HRMS (ESI): Calcd for C16H25FNO [M+H]: 266.1920; Found: 266.1924.  19F NMR (376 MHz, CDCl3, 
CFCl3 as external standard): δ -118.2. Mp: 79-81 oC. Rf  = 0.70 (EtOAc : petroleum ether = 1:2). IR 
(neat, cm-1): 2923, 2361, 1665, 1618, 1557, 1508, 1406, 1211, 835.  
  
 
 
 
1-(3-Chloro-4-methoxyphenyl)undecan-2-one (3ac). Following the general procedure D, the title 
compound was prepared using 1-(indolin-1-yl)decan-1-one (1 equiv, 0.35 mmol, 96 mg) and 2-chloro-
4-nitroanisole (1.5 equiv, 0.525 mmol, 99 mg) for reaction time of 16 h using hexanes/EtOAc/CH2Cl2 
(60:35:5) as an eluent to afford the title compound as a brown amorphous solid (89 mg, 81%). 1H NMR 
(400 MHz, CDCl3): δ 7.55 (d, J = 1.7 Hz, 1 H), 7.40-7.37 (ovlp, 2 H), 6.84 (d, J = 8.8 Hz, 1 H), 3.86 (s, 
3 H), 2.32 (d, J = 7.6 Hz, 2 H), 1.70 (d, J = 7.2 Hz, 2 H), 1.38-1.22 (m, 12 H), 0.88 (t, J = 6.5 Hz, 3 H). 
13C NMR (100 MHz, CDCl3): δ 171.7, 151.9, 131.7, 122.7, 122.5, 119.8, 112.3, 56.5, 37.7, 32.0, 29.6, 
29.5, 29.4, 25.8, 22.8, 14.2 (16 carbon signals were observed out of expected 17 carbon signals). HRMS 
(ESI): Calcd for C17H26ClNO2 [M+H]: 312.1730; Found: 312.1725.  Mp: 131-133 
oC. Rf = 0.47 (EtOAc 
: petroleum ether = 1:2). 
 
 
 
 
1-(3-Bromo-4-methylphenyl)undecan-2-one (3ad).40 Following the general procedure D, the title 
compound was prepared using 1-(indolin-1-yl)decan-1-one (1 equiv, 0.35 mmol, 96 mg) and 2-bromo-
4-nitrotoluene (1.5 equiv, 0.525 mmol, 113 mg) for reaction time of 16 h using hexanes/EtOAc/CH2Cl2 
(80:15:5) as an eluent to afford the title compound as a deep brown amorphous solid (83 mg, 70%). 1H 
NMR (400 MHz, CDCl3): δ 7.76 (s, 1 H), 7.45 (s, 1 H), 7.34 (d, J = 7.7 Hz, 1 H), 7.13 (d, J = 8.2 Hz, 1 
H), 2.36-2.29 (m, 5 H), 1.68 (quint, J = 7.3 Hz, 2 H), 1.36-1.21 (m, 12 H), 0.87 (t, J = 7.0 Hz, 3 H). 13C 
NMR (100 MHz, CDCl3): δ 171.8, 136.9, 133.6, 130.8, 124.8, 123.7, 119.0, 37.8, 32.0, 29.6, 29.5, 29.4, 
25.7, 22.8, 22.4, 14.2 (16 carbon signals were observed out of expected 17 carbon signals).  
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1-(Dibenzo[b,d]thiophen-3-yl)undecan-2-one (3ae).47 Following the general procedure D, the title 
compound was prepared using 1-(indolin-1-yl)decan-1-one (1 equiv, 0.35 mmol, 110 mg) and 3-
nitrodibenzo[b,d]thiophene (1.5 equiv, 0.525 mmol, 94 mg) for reaction time of 16 h using 
hexanes/EtOAc/CH2Cl2 (70:25:5) as an eluent to afford the title compound as an off-white amorphous 
solid (111 mg, 90%). 1H NMR (400 MHz, CDCl3): δ 8.47 (s, 1 H), 8.00 (d, J = 7.7 Hz, 1 H), 7.81-7.76 
(m, 2 H), 7.66 (d, J = 8.5 Hz, 1 H), 7.42-7.32 (m, 3 H), 2.37 (t, J = 7.7 Hz, 2 H), 1.73 (quint, J = 7.0 Hz, 
2 H), 1.36-1.19 (m, 12 H), 0.87 (t, J = 6.2 Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 172.1, 140.2, 136.2, 
135.4, 135.2, 134.9, 126.9, 124.4, 122.95, 122.85, 121.9, 119.8, 113.2, 37.9, 32.0, 29.59, 29.55, 29.5, 
29.4, 25.8, 22.8, 14.2. 
 
 
 
 
1-(2-Phenylbenzo[d]oxazol-5-yl)undecan-2-one (3af).47 Following the general procedure D, the title 
compound was prepared using 1-(indolin-1-yl)decan-1-one (1 equiv, 0.35 mmol, 96 mg) and 2-phenyl-
5-nitrobenzoxazole (1.5 equiv, 0.525 mmol, 126 mg) for reaction time of 16 h using 
hexanes/EtOAc/CH2Cl2 (70:25:5) as an eluent to afford the title compound as a deep brown amorphous 
solid (104 mg, 82%). 1H NMR (400 MHz, CDCl3): δ 8.20 (d, J = 6.8 Hz, 2 H), 7.90 (s, 1 H), 7.77 (s, 1 
H), 7.56-7.45 (m, 5 H), 2.36 (t, J = 7.6 Hz, 2 H), 1.72 (quint, J = 7.5 Hz, 2 H), 1.36-1.24 (m, 12 H), 0.86 
(d, J = 7.0 Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 171.9, 163.9, 147.6, 142.5, 135.2, 131.7, 129.0, 
127.7, 127.1, 118.5, 111.7, 110.5, 37.8, 32.0, 29.6, 29.53, 29.46, 29.4, 25.8, 22.8, 14.2. 
 
 
 
 
1-(4-(1H-Pyrazol-1-yl)phenyl)undecan-2-one (3ag).47 Following the general procedure D, the title 
compound was prepared using 1-(indolin-1-yl)decan-1-one (1 equiv, 0.35 mmol, 96 mg) and 1-(4-
nitrophenyl)-1H-pyrazole (1.5 equiv, 0.525 mmol, 99 mg) for reaction time of 16 h using 
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hexanes/EtOAc/CH2Cl2 (60:35:5) as an eluent to afford the title compound as a pale brown amorphous 
amorphous solid (69 mg, 63%). 1H NMR (400 MHz, CDCl3): δ 7.87 (s, 1 H), 7.70 (s, 1 H), 7.65-7.56 
(m, 4 H), 7.47 (s, 1 H), 6.45 (s, 1 H), 2.36 (t, J = 7.6 Hz, 2 H), 1.72 (quint, J = 7.6 Hz, 2 H), 1.41-1.20 
(m, 12 H), 0.88 (t, J = 7.0 Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 171.7, 141.0, 136.6, 136.5, 126.9, 
120.7, 120.0, 107.6, 37.9, 32.0, 29.6, 29.5, 29.43, 29.41, 25.7, 22.8, 14.2. 
 
 
 
 
N-(4-(Methylthio)phenyl)benzamide (3ah).48 Following the general procedure C, the title compound 
was prepared using (3,4-dihydroquinolin-1(2H)-yl)(phenyl)methanone (1 equiv, 0.50 mmol, 119 mg) 
and 4-nitrothioanisole (1.5 equiv, 0.75 mmol, 127 mg) using hexanes/EtOAc/Et3N (90:10:1) and then 
hexanes/EtOAc/Et3N (80:20:1) as an eluent to afford the title compound as a pale-brown amorphous 
solid (110 mg, 91%). 1H NMR (400 MHz, CD2Cl2): δ 7.90 (s, 1 H), 7.86 (d, J = 7.2 Hz, 2 H), 7.61-
7.55 (m, 3 H), 7.50 (t, J = 7.2 Hz, 2 H), 7.28 (d, J = 8.2 Hz, 2 H), 2.49 (s, 3 H). 13C NMR (100 MHz, 
CD2Cl2): δ 165.8, 136.2, 135.4, 134.4, 132.2, 129.2, 128.2, 127.4, 121.2, 16.8.  
 
 
 
 
N-(4-(4-Chlorophenoxy)phenyl)benzamide (3ai).49 Following the general procedure C, the title 
compound was prepared using (3,4-dihydroquinolin-1(2H)-yl)(phenyl)methanone (1 equiv, 0.50 mmol, 
119 mg) and 1-chloro-4-(4-nitrophenoxy)benzene (1.5 equiv, 0.75 mmol, 187 mg) using 
hexanes/EtOAc/Et3N (90:10:1) and then hexanes/EtOAc/Et3N (80:20:1) as an eluent to afford the title 
compound as an off-white amorphous solid (73 mg, 45%). 1H NMR (400 MHz, CDCl3): δ 7.90 (s, 1 
H), 7.87 (d, J = 7.4 Hz, 2 H), 7.61 (d, J = Hz, 2 H), 7.55 (t, J = 7.4 Hz, 1 H), 7.48 (t, J = 7.6 Hz, 2 H), 
7.28 (d, J = 8.8 Hz, 2 H), 7.01 (d, J = 8.8 Hz, 2 H), 6.93 (d, J = 8.8 Hz, 2 H). 13C NMR (100 MHz, 
CDCl3): δ 165.9, 156.3, 153.4, 134.9, 133.9, 132.1, 129.9, 129.0, 128.2, 127.1, 122.2, 119.9, 119.8.  
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Ccyclohexyl(1H-indol-1-yl)methanone (3aj).50 Following the general procedure C, the title compound 
was prepared using cyclohexyl(1H-indol-1-yl)methanone (1 equiv, 0.50 mmol, 114 mg) and 4-
nitroanisole (1.5 equiv, 0.75 mmol, 115 mg) using hexanes/EtOAc/Et3N (90:10:1) and then 
hexanes/EtOAc/Et3N (80:20:1) as an eluent to afford the title compound as a pale brown amorphous 
solid (81 mg, 69%). 1H NMR (400 MHz, CD2Cl2): δ 7.46-7.35 (m, 3 H), 6.83 (d, J = 8.2 Hz, 2 H), 3.77 
(s, 3 H), 2.19 (t, J = 11.2 Hz, 1 H), 1.95-1.87 (m, 2 H), 1.84-1.76 (m, 2 H), 1.71-1.64 (m, 1 H), 1.54-
1.45 (m, 2 H), 1.36-1.19 (m, 3 H). 13C NMR (100 MHz, CD2Cl2): δ 174.6, 156.6, 131.9, 122.1, 114.3, 
55.8, 46.6, 30.1, 26.2, 26.1.  
 
 
 
 
N-(4-methoxyphenyl)-2-methylbenzamide (3ak).44 Following the general procedure C, the title 
compound was prepared using (9H-carbazol-9-yl)(o-tolyl)methanone (1 equiv, 0.33 mmol, 93 mg), 4-
nitroanisole (1.5 equiv, 0.495 mmol, 76 mg), phen (10 mol %, 6 mg), Mn (5 equiv, 91 mg), TMSI (1 
equiv, 0.33 mmol, 47 μL), and NMP (0.7 mL) using hexanes/EtOAc/Et3N (90:10:1) and then 
hexanes/EtOAc/Et3N (80:20:1) as an eluent to afford the title compound as an off-white amorphous 
solid (74 mg, 61%). 1H NMR (400 MHz, CDCl3): δ 7.63 (s, 1 H), 7.49 (d, J = 7.3 Hz, 2 H), 7.40 (d, J 
= 6.0 Hz, 1 H), 7.32 (t, J = 6.3 Hz, 1 H), 7.25-7.16 (m, 2 H), 6.86 (d, J = 7.3 Hz, 2 H), 3.79 (s, 3 H), 
2.45 (s, 3 H). 13C NMR (100 MHz, CDCl3): δ 168.1, 156.6, 136.6, 136.4, 131.2, 130.2, 126.7, 125.9, 
121.9, 114.3, 55.6, 19.9 (12 carbon signals were observed out of expected 13 carbon signals).  
 
 
 
 
N-(4-(Phenylthio)phenyl)cyclopropanecarboxamide (3al).51 Following the general procedure C, the 
title compound was prepared using (9H-carbazol-9-yl)(cyclopropyl)methanone (1 equiv, 0.50 mmol, 
118 mg) and (4-nitrophenyl)(phenyl)sulfane (1.5 equiv, 0.75 mmol, 173 mg) using hexanes/EtOAc/Et3N 
(90:10:1) and then hexanes/EtOAc/Et3N (70:30:1) as an eluent to afford the title compound as an off-
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white amorphous solid (108 mg, 80%). 1H NMR (400 MHz, CDCl3): δ 7.70 (s, 1 H), 7.49 (d, J = 7.2 
Hz, 2 H), 7.34 (d, J = 8.1 Hz, 2 H), 7.27-7.15 (m, 5 H), 1.55-1.45 (m, 1 H), 1.10-1.02 (m, 2 H), 0.89-
0.79 (m, 2 H). 13C NMR (100 MHz, CDCl3): δ 172.3, 137.9, 137.1, 133.3, 129.7, 129.5, 129.2, 126.6, 
120.6, 15.9, 8.3.  
 
 
 
 
N-(4-(4-Benzoylphenoxy)phenyl)cyclopropanecarboxamide (3am). Following the general procedure 
C, the title compound was prepared using (9H-carbazol-9-yl)(cyclopropyl)methanone (1 equiv, 0.50 
mmol, 118 mg) and (4-(4-nitrophenoxy)phenyl)(phenyl)methanone (1.5 equiv, 0.75 mmol, 239 mg) 
using hexanes/EtOAc/Et3N (90:10:1) and then hexanes/EtOAc/Et3N (60:40:1) as an eluent to afford the 
title compound as a pale brown amorphous solid (117 mg, 65%). 1H NMR (400 MHz, CDCl3): δ 7.81-
7.71 (m, 5 H), 7.60-7.55 (m, 3 H), 7.48 (t, J = 7.6 Hz, 2 H), 7.05 (d, J = 8.6 Hz, 2 H), 6.99 (t, J = 8.5 
Hz, 2 H), 1.59-1.48 (m, 1 H), 1.14-1.03 (m, 2 H), 0.90-0.79 (m, 2 H). 13C NMR (100 MHz, CDCl3): δ 
195.8, 172.2, 162.1, 151.4, 138.0, 135.1, 132.6, 132.3, 131.8, 129.9, 128.4, 121.6, 121.0, 116.9, 15.8, 
8.2. HRMS (ESI): Calcd for C23H20NO3 [M+H]: 358.1443; Found: 358.1431. Mp: 175-177 
oC. Rf  = 
0.30 (EtOAc : petroleum ether = 1:2). IR (neat, cm-1): 3282, 1650, 1598, 1552, 1503, 1249, 939, 835.  
 
 
 
 
1-(Quinolin-6-yl)undecan-2-one (3an).40 Following the general procedure D, the title compound was 
prepared using 1-(1H-pyrazol-1-yl)decan-1-one (1 equiv, 0.35 mmol, 78 mg) and 6-nitroquinoline (1.5 
equiv, 0.525 mmol, 91 mg) for reaction time of 16 h using hexanes/EtOAc/CH2Cl2 (20:75:5) as an eluent 
to afford the title compound as a pale brown amorphous solid (43 mg, 42%). 1H NMR (400 MHz, 
CDCl3): δ 8.81 (s, 1 H), 8.70 (s, 1 H), 8.45 (s, 1 H), 8.05 (d, J = 8.4 Hz, 1 H), 7.98 (d, J = 9.0 Hz, 1 H), 
7.61 (d, J = 9.1 Hz, 1 H), 7.34 (dd, J = 8.4 Hz, J = 4.3 Hz, 1 H), 2.42 (t, J = 7.6 Hz, 2 H), 1.74 (quint, J 
= 7.7 Hz, 2 H), 1.36-1.17 (m, 12 H), 0.86 (t, J = 7.1 Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 172.5, 
149.2 145.4, 136.5, 136.1, 129.8, 129.0, 123.5, 121.7, 116.2, 37.8, 31.9, 29.50, 29.47, 29.39, 29.3, 25.8, 
22.7, 14.2.   
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N-(4-(tert-butyl)phenyl)adamantane-1-carboxamide (3ao).40 Following the general procedure C, the 
title compound was prepared using (adamantan-1-yl)(1H-pyrazol-1-yl)methanone (1 equiv, 0.50 mmol, 
116 mg) and 1-(tert-butyl)-4-nitrobenzene (1.5 equiv, 0.75  mmol, 128 μL) using hexanes/EtOAc/Et3N 
(90:10:1) as an eluent to afford the title compound as an off-white amorphous solid (59 mg, 38%). 1H 
NMR (400 MHz, CD2Cl2): δ 7.46 (d, J = 8.6 Hz, 2 H), 7.38 (s, 1 H), 7.34 (d, J = 8.6 Hz, 2 H), 2.09-
2.05 (m, 3 H), 1.96-1.93 (m, 6 H), 1.80-1.72 (m, 6 H), 1.31 (s, 9 H). 13C NMR (100 MHz, CD2Cl2): δ 
176.2, 147.4, 136.2, 126.0, 120.3, 41.8, 39.7, 36.9, 34.6, 31.5, 28.8.  
 
 
 
N-(p-tolyl)-4-(trifluoromethyl)benzamide (3ap).52  
 
Reaction 1: Following the general procedure C, the title compound was prepared using pyrrolidin-1-
yl(4-(trifluoromethyl)phenyl)methanone (1 equiv, 0.50 mmol, 122 mg), 4-nitrotoluene (3 equiv, 1.5 
mmol, 206 mg), phen (20 mol %, 18 mg), Mn (10 equiv, 276 mg), and TMSI (2 equiv, 143 μL) using 
hexanes/EtOAc/Et3N (90:10:1) and then hexanes/EtOAc/Et3N (80:20:1) as an eluent to afford the title 
compound as an off-white amorphous solid (85 mg, 61%). 1H NMR (600 MHz, DMSO-d6): δ 10.37 (s, 
1 H), 8.14 (d, J = 7.9 Hz, 2 H), 7.90 (d, J = 8.0 Hz, 2 H), 7.66 (d, J = 8.0 Hz, 2 H), 7.17 (d, J = 8.0 Hz, 
2 H), 2.29 (s, 3 H). 13C NMR (150 MHz, DMSO-d6): 164.1, 138.8, 136.3, 133.0, 131.2 (q, 
2JCF = 31.6 
Hz), 129.0, 128.5, 125.3 (q, 2JCF = 3.6 Hz), 123.9 (q, 
1JCF = 271.1 Hz), 120.4, 20.5.  
 
 
Reaction 2: Following the general procedure C, the title compound was prepared using piperidin-1-
yl(4-(trifluoromethyl)phenyl)methanone (1 equiv, 0.50 mmol, 129 mg), 4-nitrotoluene (3 equiv, 1.5 
mmol, 206 mg), phen (20 mol %, 18 mg), Mn (10 equiv, 276 mg), and TMSI (2 equiv, 143 μL) using 
hexanes/EtOAc/Et3N (90:10:1) and then hexanes/EtOAc/Et3N (80:20:1) as an eluent to afford the title 
compound as an off-white solid (67 mg, 48%). Spectral and analytical data were identical to those 
reported for the same compound above. 
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N-(4-(tert-Butyl)phenyl)-3,4,5-trimethoxybenzamide (4a). Following the general procedure D, the 
title compound was prepared using indolin-1-yl(3,4,5-trimethoxyphenyl)methanone (1 equiv, 0.35 
mmol, 110 mg) and 1-(tert-butyl)-4-nitrobenzene (1.5 equiv, 0.525 mmol, 94 mg) using 
hexanes/EtOAc/CH2Cl2 (40:55:5) as an eluent to afford the title compound as pale brown amorphous 
solid (50 mg, 42%). 1H NMR (600 MHz, CDCl3): δ 7.68 (s, 1 H), 7.55 (d, J = 5.8 Hz, 2 H), 7.40 (d, J 
= 5.8 Hz, 2 H), 7.07 (s, 2 H), 3.93 (s, 6 H), 3.91 (s, 3 H), 1.33 (s, 9 H). 13C NMR (100 MHz, CDCl3): δ 
165.7, 153.3, 147.6, 141.1, 135.5, 130.7, 125.9, 120.3, 104.7, 61.0, 56.4, 34.5, 31.5. HRMS (ESI): Calcd 
for C20H26NO4 [M+H]: 344.1862; Found: 344.1862. Mp: 158-160 
oC. Rf  = 0.49 (EtOAc : petroleum 
ether = 1:2). 
 
 
 
 
N-(2-Phenylbenzo[d]oxazol-5-yl)benzamide (4b).40 Following the general procedure D, the title 
compound was prepared using N-methyl-N-phenylbenzamide (1 equiv, 0.35 mmol, 74 mg) and 5-nitro-
2-phenylbenzo[d]oxazole (1.5 equiv, 0.525 mmol, 126 mg) using hexanes/EtOAc/CH2Cl2 (70:25:5) as 
an eluent to afford the title compound as a brown amorphous solid (88 mg, 80%). 1H NMR (400 MHz, 
CDCl3): δ 8.23 (d, J = 4.6 Hz, 2 H), 8.12 (s, 1 H), 8.03 (s, 1 H), 7.89 (d, J = 6.7 Hz, 2 H), 7.65 (d, J = 
7.7 Hz, 1 H), 7.57-7.44 (m, 7 H). 13C NMR (100 MHz, CDCl3): δ 166.1, 164.1, 148.0, 142.7, 135.01, 
134.98, 132.0, 131.8, 129.0, 128.9, 127.8, 127.2, 127.1, 118.9, 112.3, 110.7.  
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 S94   
1H and 13C NMR of N-(4-(tert-butyl)phenyl)adamantane-1-carboxamide (3ao). 
 
 S95   
1H and 13C NMR of N-(p-tolyl)-4-(trifluoromethyl)benzamide (3ap).  
 
 S96   
1H and 13C NMR of N-(4-(tert-butyl)phenyl)-3,4,5-trimethoxybenzamide (4a).  
 
 S97   
1H and 13C NMR of N-(2-Phenylbenzo[d]oxazol-5-yl)benzamide (4b).  
 
